Sinovac’s antibodies drops below threshold after six months based on study findings

CHINA – According to a lab study, antibodies triggered by Sinovac Biotech’s COVID-19 vaccine declined below a key threshold from around six months after a second dose for most recipients, although a third shot had a strong booster effect. Chinese researchers reported the findings from a study of blood samples from healthy adults aged between 18-59 in a paper published on Sunday, though it was not peer reviewed. Among participants who received two doses, two or four weeks apart, only 16.9% and 35.2% respectively still had neutralizing antibodies above what…

Read More

China’s Sinopharm vaccine gaining popularity in Africa, as Tunisia grants approval

TUNISIA – Tunisian Ministry of Health has announced that China’s Sinopharm COVID-19 vaccine has been officially approved for marketing in the country. “The Ministry of Health has granted an exceptional and provisional marketing authorization in the Tunisian market for China’s Sinopharm COVID-19 vaccine,” said a ministry statement. The marketing authorization was granted after the issue was evaluated by the specialized committee in the field of virology, toxicology and the Technical Committee for Pharmaceutical Specialties. Since the start of the national vaccination campaign against the coronavirus on March 13, a total…

Read More

GAVI inks deal with Sinopharm and Sinovac to supply vaccines to COVAX

AFRICA – The Vaccine Alliance (GAVI) has announced that it has signed advance purchase agreements with Sinopharm and Sinovac for immediate supply of Sinopharm’s “BBIBP-Corv” vaccine and Sinovac’s “CoronaVac” vaccine to the COVAX facility. COVAX largely ensures adequate and equitable supply of vaccines to Africa. So far, they have managed to supply 25 million cases. Nineteen countries have used more than 80% of their COVAX-supplied doses, while 31 countries have used more than 50%. In the past two weeks, more than 1.6 million doses were delivered to Africa through COVAX.…

Read More